证券研究报告·公司点评报告·医疗服务 2025 年 04 月 29 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 证券分析师 刘若彤 执业证书：S0600525040006 2024 年报&2025 年一季报点评：利润短期承 压，海外业务维持高增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 622.19 | 686.84 | 814.88 | 935.27 | 1,067.83 | | 同比（%） | 20.45 | 10.39 | 18.64 | 14.77 | 14.17 | | 归母净利润（百万元） | 158.91 | 109.82 | 132.74 | 161.11 | 196.15 | | 同比（%） | (3.49) | (30.89) | 20.87 | 21.38 | 21.75 | | EPS-最新摊薄（元/股） | 0.39 | 0 ...

证券研究报告·公司点评报告·通用设备 2025Q1 公司毛利率为 32.02%，同比-0.97pct。公司毛利率小幅下降，我 们判断系收入结构变化与在建工程转固导致折旧提升。 新锐股份（688257） 2025 年一季报点评：业绩稳步提升，加速拓 展布局海外市场 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,549 | 1,862 | 2,456 | 2,929 | 3,495 | | 同比（%） | 30.89 | 20.17 | 31.94 | 19.24 | 19.32 | | 归母净利润（百万元） | 162.99 | 180.73 | 225.22 | 275.34 | 332.45 | | 同比（%） | 10.94 | 10.89 | 24.61 | 22.25 | 20.74 | | EPS-最新摊薄（元/股） | 0.90 | 1.00 | 1.24 | 1.52 | 1.84 | | P ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights stable growth across various business segments, with notable performance in investment net income [1] - The company achieved a significant increase in total revenue and net profit in Q1 2025, with total revenue reaching 17.76 billion and net profit at 6.55 billion, representing year-on-year growth of 29.1% and 32.0% respectively [8] - The brokerage business saw a substantial increase in revenue due to a surge in trading volume, while investment income also experienced significant growth [8] Financial Performance Summary - Total revenue forecast for 2023A is 60.068 billion, with a projected increase to 70.842 billion by 2025E, reflecting a year-on-year growth of 11.06% [1] - Net profit attributable to shareholders is expected to rise from 19.721 billion in 2023A to 25.669 billion in 2025E, indicating an 18.27% increase [1] - The latest diluted EPS is projected to be 1.73 for 2025E, with a P/E ratio of 15.58 [1] Business Segment Performance - Brokerage revenue increased by 36.2% year-on-year, contributing 20.5% to total revenue [8] - Investment banking revenue grew by 12.2%, with a significant increase in underwriting scale [8] - Asset management revenue rose by 8.7%, maintaining the company's leading position in the market [8] - Investment income saw a remarkable increase of 62.3% year-on-year, with adjusted net investment income up by 35.6% [8]

证券研究报告·公司点评报告·环境治理 赛恩斯（688480） 2024年报&2025一季报点评：业务结构改善， 出海&紫金合作持续推进 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 808.41 | 927.19 | 1,292.60 | 1,609.73 | 1,888.80 | | 同比（%） | 47.47 | 14.69 | 39.41 | 24.53 | 17.34 | | 归母净利润（百万元） | 90.33 | 180.76 | 195.80 | 245.16 | 288.42 | | 同比（%） | 36.39 | 100.11 | 8.32 | 25.21 | 17.64 | | EPS-最新摊薄（元/股） | 0.95 | 1.90 | 2.05 | 2.57 | 3.03 | | P/E（现价&最新摊薄） | 34.71 | 17.35 | 16.01 | 12.79 | 10.87 | ...

证券研究报告·公司点评报告·调味发酵品Ⅱ 证券分析师 苏铖 执业证书：S0600524120010 such@dwzq.com.cn 天味食品（603317） 2025 年一季报点评：短期调整致业绩承压， 轻装上阵改善可期 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,149 | 3,476 | 3,655 | 4,019 | 4,443 | | 同比（%） | 17.02 | 10.41 | 5.16 | 9.94 | 10.54 | | 归母净利润（百万元） | 456.70 | 624.64 | 626.63 | 706.32 | 797.71 | | 同比（%） | 33.65 | 36.77 | 0.32 | 12.72 | 12.94 | | EPS-最新摊薄（元/股） | 0.43 | 0.59 | 0.59 | 0.66 | 0.75 | | P/E（现价&最新摊薄） | 27.10 | 1 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 3.72 billion yuan in Q1 2025, representing a year-on-year increase of 2.1%. However, the net profit attributable to shareholders decreased by 22.4% year-on-year to 230 million yuan [7] - The offline distribution channels have begun to ramp up, with a total growth of 16.2% when combining Q4 2024 and Q1 2025. In Q1 2025, online channels accounted for approximately 70% of revenue, while offline distribution and supermarkets made up nearly 30% [7] - The company is in the phase of introducing distribution, which has led to some pressure on expenses. The gross profit margin for Q1 2025 was 26.7%, a decrease of 0.7 percentage points year-on-year [7] - The company expects to improve net profit margins through increased sales of daily consumer goods and dairy beverages in offline distribution, as well as a gradual increase in the self-production ratio of nuts [7] - The profit forecast remains unchanged, with expected net profits for 2025-2027 at 4.95 billion, 7.11 billion, and 11.11 billion yuan, respectively, reflecting year-on-year growth rates of 21%, 44%, and 56% [7] Financial Summary - Total revenue is projected to reach 10.62 billion yuan in 2024, with a year-on-year growth of 49.3%, and further increase to 20.41 billion yuan by 2027 [1] - The net profit attributable to shareholders is expected to grow from 407.74 million yuan in 2024 to 1.11 billion yuan in 2027, with a year-on-year growth of 85.51% in 2024 [1] - The latest diluted EPS is forecasted to be 1.02 yuan in 2024, increasing to 2.76 yuan by 2027 [1]

买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 808.41 | 927.19 | 1,292.60 | 1,609.73 | 1,888.80 | | 同比（%） | 47.47 | 14.69 | 39.41 | 24.53 | 17.34 | | 归母净利润（百万元） | 90.33 | 180.76 | 195.80 | 245.16 | 288.42 | | 同比（%） | 36.39 | 100.11 | 8.32 | 25.21 | 17.64 | | EPS-最新摊薄（元/股） | 0.95 | 1.90 | 2.05 | 2.57 | 3.03 | | P/E（现价&最新摊薄） | 34.71 | 17.35 | 16.01 | 12.79 | 10.87 | [Table_Tag] [投资要点 Table_Summary] 证券研究报告·公司点评报告·环境治理 2025 年 04 月 29 日 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term pressure but is expected to improve gradually quarter by quarter [1] - In 2024, the company achieved total revenue of 36.726 billion yuan, a year-on-year increase of 5.14%, and a net profit attributable to shareholders of 11.668 billion yuan, a year-on-year increase of 0.74% [7] - The company anticipates a turning point in 2025, despite short-term challenges in the domestic market [7] Financial Performance Summary - Total revenue projections for the company are as follows: 39.369 billion yuan in 2025, 45.061 billion yuan in 2026, and 52.403 billion yuan in 2027, with respective year-on-year growth rates of 7.20%, 14.46%, and 16.29% [1] - Net profit attributable to shareholders is projected to be 11.960 billion yuan in 2025, 13.131 billion yuan in 2026, and 15.280 billion yuan in 2027, with year-on-year growth rates of 2.50%, 9.79%, and 16.37% [1] - The latest diluted EPS is expected to be 9.86 yuan in 2025, 10.83 yuan in 2026, and 12.60 yuan in 2027 [1] Business Segment Performance - The Life Information and Support business generated revenue of 13.557 billion yuan in 2024, a decrease of 11.11% year-on-year, while the International Life Information and Support business saw double-digit growth [7] - The In Vitro Diagnostics (IVD) business achieved revenue of 13.765 billion yuan, a year-on-year increase of 10.82%, marking its first time exceeding the Life Information and Support business in revenue [7] - The Medical Imaging segment generated revenue of 7.498 billion yuan, with international business growth exceeding 15% [7] - The Electrophysiology and Vascular Intervention segment generated revenue of 1.439 billion yuan, with the acquisition of control over Huitai Medical to enhance cardiovascular segment capabilities [7] Innovation and Growth Drivers - The company launched several innovative products in 2024, including advanced medical systems and AI-driven solutions to improve patient care and operational efficiency [7] - The company maintains a strong competitive position due to its diverse product lines and continuous innovation [7]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company demonstrates resilience as a market leader, with steady progress expected in 2025 [1] - The revenue for 2024 is projected to be 15.13 billion yuan, reflecting a year-on-year growth of 7.7% [7] - The net profit attributable to shareholders for 2024 is expected to be 1.485 billion yuan, with a slight increase of 0.46% year-on-year [7] - The report highlights that the hot pot ingredient products show better performance than the industry average, with a revenue of 7.84 billion yuan in 2024, up 11% year-on-year [7] - The company’s profit margins remain stable despite pressures from raw material costs and promotions [7] Financial Forecasts - Total revenue is forecasted to grow from 15.13 billion yuan in 2024 to 18.22 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 5.01% [1][8] - The net profit attributable to shareholders is projected to increase from 1.625 billion yuan in 2025 to 1.96 billion yuan in 2027, representing a CAGR of about 7% [1][8] - The earnings per share (EPS) is expected to rise from 5.54 yuan in 2025 to 6.68 yuan in 2027 [1][8] Financial Ratios - The price-to-earnings (P/E) ratio is projected to decrease from 13.30 in 2025 to 11.03 in 2027, indicating a potentially attractive valuation [1][8] - The gross margin for 2024 is estimated at 23.3%, with a slight decline expected in subsequent years [8] - The return on equity (ROE) is forecasted to improve from 12.02% in 2025 to 13.23% in 2027 [8]

证券研究报告·公司点评报告·通用设备 华锐精密（688059） 2024 年报&2025 年一季报点评：25Q1 业绩 重回增长区间，股权激励结束费用边际改善 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 794.27 | 759.06 | 957.40 | 1,181.40 | 1,463.90 | | 同比（%） | 32.02 | (4.43) | 26.13 | 23.40 | 23.91 | | 归母净利润（百万元） | 157.91 | 106.96 | 156.53 | 210.61 | 272.78 | | 同比（%） | (4.85) | (32.26) | 46.35 | 34.55 | 29.52 | | EPS-最新摊薄（元/股） | 2.54 | 1.72 | 2.51 | 3.38 | 4.38 | | P/E（现价&最新摊薄） | 22.59 | 33.35 | 22.79 | 1 ...